WallStSmart

Amphenol Corporation (APH)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amphenol Corporation generates 368% more annual revenue ($25.90B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 17.2%. APH appears more attractively valued with a PEG of 1.17. RMD earns a higher WallStSmart Score of 74/100 (B).

APH

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 9.0Value: 6.7Quality: 6.8
Piotroski: 4/9Altman Z: 2.36

RMD

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APHUndervalued (+53.3%)

Margin of Safety

+53.3%

Fair Value

$312.78

Current Price

$122.47

$190.31 discount

UndervaluedFair: $312.78Overvalued
RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$198.76

$30.82 premium

UndervaluedFair: $229.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APH5 strengths · Avg: 9.0/10
Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

Revenue GrowthGrowth
58.4%10/10

Revenue surging 58.4% year-over-year

Market CapQuality
$168.07B9/10

Large-cap with strong market position

Operating MarginProfitability
27.3%8/10

Strong operational efficiency at 27.3%

EPS GrowthGrowth
24.1%8/10

Earnings expanding 24.1% YoY

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Areas to Watch

APH2 concerns · Avg: 4.0/10
P/E RatioValuation
39.3x4/10

Premium valuation, high expectations priced in

Price/BookValuation
10.8x4/10

Trading at 10.8x book value

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : APH

The strongest argument for APH centers on Return on Equity, Revenue Growth, Market Cap. Profitability is solid with margins at 17.2% and operating margin at 27.3%. Revenue growth of 58.4% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : APH

The primary concerns for APH are P/E Ratio, Price/Book.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

APH profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

APH carries more volatility with a beta of 1.30 — expect wider price swings.

APH is growing revenue faster at 58.4% — sustainability is the question.

APH generates stronger free cash flow (830M), providing more financial flexibility.

Bottom Line

APH scores higher overall (74/100 vs 74/100), backed by strong 17.2% margins and 58.4% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphenol Corporation

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Amphenol Corporation is a major producer of electronic and fiber optic connectors, cable and interconnect systems such as coaxial cables. Amphenol is a portmanteau from the corporation's original name, American Phenolic Corp.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?